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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
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ABSTRACT:
The novel coronavirus (COVID-19) can result in several neurological complications including Guillain-Barré Syndrome 
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involvement. Two patients had bilateral abducent nerve palsy while two presented as paraparetic GBS variant with 
autonomic dysfunction. Electrodiagnostics studies were conducted in 17 patients only and 12 had typical features of 
acute inflammatory demyelinating polyradiculoneuropathy. Intravenous immunoglobulin was the preferred mode of 
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response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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INTRODUCTION:
The novel coronavirus (COVID-19) infection originated 
from Huanan seafood market in Wuhan city China in 
December 2019. It rapidly spread to more than 200 
countries of the world. The World Health Organization 
(WHO) has reported more than 166 million cases all 
around the globe with a death toll more than 34 
million.1 COVID-19 primarily affects the respiratory tract 
and the lungs. However, other organs including 
cardiovascular, renal, and neurological system have 
also been reported. The reported neurological 
manifestations and complications of COVID-19 include 
anosmia, headaches, dizziness, delirium, stroke, 
epilepsy, encephalitis, encephalopathy, myalgia and 
Guillain-Barr é syndrome (GBS),2,3,4 This review 
summarizes the important demographic features, 
clinical presentation, diagnostics, and management 
strategies of COVID-19 associated GBS reported in 
literature so far. We inform the readers about this 
important neurological manifestation of COVID-19 in 
order to formulate better diagnostic and management 
strategies.
Pathophysiology and Clinical Features of 
Guillain-Barr é syndrome
GBS is acute onset immune mediated disorder 
characterized by rapidly progressive limbs and bulbar 
weakness which can lead to respiratory failure.5 Many 
triggers for GBS have been identified including bacterial 
and viral infections, surgery, and pregnancy. The link of 
GBS with vaccination is controversial. Respiratory and 
Gastrointestinal infections constitute two third of cases. 
The molecular mimicry between the cell membrane 
antigen of microbe and ganglioside component of nerve 
antigen misdirects the immune response. This immune 
response is humoral mediated and not T cell mediated. 
The prototype example is of Campylobacter Jejuni 
infection. The carbohydrate moiety of 
liopooligosaccahrides of Campylobacter Jejuni is 
capable of inducing antibodies that cross react with 
glycans present on nerve gangliosides.6 The exact 
trigger to mount this misdirected immune response is 
still not known. There is no specific genetic 
predisposition as only 1% of all campylobacter 
infections will result in GBS. GBS has also been 
reported after viral infections for example 
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika, 
and Chikungunya virus.9,13 The clinical hallmark is 
hyporeflexia or areflexia. The course of the disease is 
monophasic. Recommended treatment for GBS 
includes plasmapheresis (PLEX) and immunoglobulins 
(IVIG) infusion.7 GBS was initially described only as a 
demyelinating polyneuropathy. Typical features of 
demyelination on electrodiagnostic studies (EDX) 
include prolong distal latencies, reduction of 
conduction velocity, prolong F-waves, temporal 
dispersion, and conduction block.  Clinically many 
different variants with distinct clinical and 
electrophysiological features have been reported in 
literature.8 These include cranial, autonomic, ataxic, 
paraparetic and mixed variety. The GBS reported from 
North America and Europe is predominantly 
demyelinating type while in Asian countries the axonal 
type of GBS constitutes 30-50 % of the reported cases. 
9,10,11,12 The mortality of GBS reported from European 
and North American studies ranges from 3-7%, and is 
mainly due to respiratory failure, deep vein thrombosis 
and autonomic dysfunction.  The axonal variants of 
GBS mostly reported in the Chinese and Asians 
populations have a poor prognosis i.e. slower recovery 
and prolonged disability.13 In case of axonal variant of 
GBS, once the axonal integrity is damaged, it does not 
be regenerate actively and completely. 1
Neurological injury due to Coronavirus 
Coronaviruses are not primarily neurotropic viruses, and 
their primary target is respiratory and cardiovascular 
systems. However other organs including 
gastrointestinal tract, renal, eyes and nervous system 
can also be involved. It is through the 
Angiotensin-converting enzyme 2 (ACE-2) receptors the 
virus is attached to host cells leading to internalization 
and subsequent   viral replication. This receptor is also 
found in glial cells in the Central Nervous System (CNS) 
and spinal neurons. Very rarely the virus can invade 
peripheral nerves and lead to retrograde transfer via 
synapse mediated route to CNS. Another proposed 
route of entry is through the olfactory nerves.14,15 Past 
experience with  Severe Acute Respiratory Syndrome 
(SARS) and Middle East Respiratory syndrome (MERS) 
related cases has also provided insights into the neuro 
invasive potential of Coronaviruses.16,17 As the number 
of COVID-19 cases with neurological manifestations 
and complications are being reported more frequently, 
there is  growing evidence for neurotoxic potential of 
COVID-19.  This neurotoxicity can occur because of 
direct or indirect insult by virus and may manifest in 
form of post-infectious complications like GBS. In this 
review we will focus only on the post infectious 
complications.
Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves, 
nerve roots, or anterior horn cells leading to 
inflammation and death of motor neurons as seen in 
polio virus or West Nile virus.  The Cerebrospinal fluid 
(CSF) Polymerase chain reaction (PCR) for coronavirus 
in multiple reported cases of COVID-19 related GBS 
has been negative.19 It is likely a post infectious or may 
be a para-infectious complication resulting from an 
aberrant immune response. During the inflammatory 
phase numerous mediators of inflammation are 
released from activated leukocytes including 
Interleukin-6 (IL-6), named as Cytokine storm. This can 
result in major organ damage, rapid deterioration of the 
patient and ultimately death.20 However, due to lack of 
experimental data it is difficult to deduct if IL-6 is also 
responsible for the   neurological damage.36 However, 
after the acute phase of the infection, an immune 
response is generated by the host and may lead to a 
misdirected reaction against host epitopes. It can result 
in an autoimmune, response directed against 
peripheral nerves and nerve roots in susceptible 
individuals.  This may be either demyelinating or axonal 
degeneration type. This results in a typical GBS like 
presentation in the peripheral nerves and spinal roots. 
However, due to lack of clear data, there is still not 
enough evidence available to conclude if antibodies to 
any specific ganglioside antigen are present in these 
cases or not. There is also speculation that the 
neuropathy in viral infections related GBS could be due 
to other autoantibodies that are not detected as yet, or 
the viruses produced nerve damage due to other 
neurotoxic effects.
Literature Search strategy
We searched Medline, PubMed Central and Google 
Scholar using keywords “COVID-19”, “Coronavirus”, 
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV 
“.“pandemic”, “SARS-COV-2”, “neurology”, 
“neurological”, “complications”, “manifestations”, 
“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory 
demyelinating polyneuropathy”,” Demyelinating 
Polyradiculoneuropathy”,   “polyneuropathy”, and “Miller 
Fisher syndrome”. Different combinations of Boolean 
logic (AND, OR and NOT) were used to identify relevant 
articles. Search was limited only to English language 
manuscripts with no time limit. It is important to note 
that new data is being shared regularly and at the time of 
the literature search it consisted mostly of pre-prints, 
letters to editor, single case reports, small case series, 
and part of an article describing clinical features of 
COVID-19. Most of the data on COVID-19 is published 
from countries most severely affected, including China, 
Italy, Spain, and USA.  The last literature search was 
done on 18th May 2020. At that time there was no 
specific research article, systematic or narrative review 
describing COVID-19 associated GBS. However, we 
identified two systematic reviews protocols on this topic 
registered in the International prospective register of 
systematic reviews.21,22 Both authors independently 
performed the literature search and compared the 
results for any major discrepancies. The information was 
extracted on a pre-designed data sheet. The items of 
interest were the demographic data, presenting features, 
clinical examination, laboratory and radiological 
investigations, treatment protocol and outcomes. Due to 
the limited number of cases and nature of the review, a 
quantitative analysis was not done, and we have only 
provided a qualitative review of the retrieved information. 
This was a scoping literature review of the published data 
and did not involve interaction with humans or primary 
data collection. Therefore, a formal ethics review 
committee approval was not obtained. 
 
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and 
unrelated articles, we identified 24 cases of GBS in 
COVID-19, published in English biomedical literature till 
18th May 2020. These were published as letter to editor, 
case reports or case series. The results are summarized 
in the Tables 1 and 2.
Demographics 
Most of the cases (8) were reported from Italy23,24,25,26 
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain 
(3 cases),32,33 Germany (2 cases)34,35 and one case each 
from China36, France37, Switzerland38 and Morocco.39 
Majority of the patients were males 18(/75%). The age 
ranged from 23-84 years and mean age was 60 years.
Clinical Features
Most of the patients (17/24) had typical presenting 
features of GBS with sensory paresthesia followed by 
ascending paralysis. Three patients had Miller Fisher 
variant presenting as ataxia, ophthalmoplegia and 
areflexia. One case had only bilateral facial palsy without 
any peripheral manifestations and was labeled as facial 
diplegic variant of GBS. One case each from the US30 
and Switzerland 40  initially presented with paraparesis 
and bladder and bowel dysfunction. Spinal cord imaging 
was normal in both these cases and these were labeled 
as paraparetic variant with autonomic dysfunction Total 
of nine patient developed facial palsy out of which six had 
bilateral facial palsy. Two patients developed bilateral six 
nerve palsy. One patient among above who initially 
presented with bilateral facial and hypoglossal palsy and 
progressed to a locked in syndrome like condition.  An 
important peripheral nervous manifestation i.e., 
hyposmia and hypogeusia was reported in Five patients. 
One of them had complete reversal of hyposmia at the 
time of discharge. The predominant clinical presentation 
in majority of the cases was post-infectious. However, in 
three cases the onset of symptoms suggested a 
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR 
positive for COVID-19, except one case. That patient 
repeatedly tested negative but, later his serology tested 
positive for COVID-19. CSF PCR for COVID-19 was tested 
in twelve patients and it was negative in all. Ganglioside 
antibody was tested in twelve cases. Ganglioside Ab 
GM2 IgG/IgM  and  GD 1b were  positive in one case 
each only. One of them was the Miller Fisher Variant. 
CSF analysis was performed in 20 cases. Four patients 
had a normal CSF analysis while in 16 cases it showed 
albuminocytological dissociation of GBS. COVID-19 
associated lung changes were detected on 
High-Resolution Chest Tomography (HRCT) chest in 
fourteen cases. X-ray chest was normal in six cases and 
revealed pneumonia in one case. Chest imaging was not 
reported in two cases. This can potentially guide the 
clinicians. During this pandemic, in a patient with GBS, 
HRCT chest should be ordered in case of any doubt to 
detect possible COVID-19 associated pneumonia as 
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG) 
were performed in 17 cases.  Out of these twelve cases 
had prolongation of distal latencies (DML) and absent F 
waves suggestive of a typical demyelinating 
polyneuropathy.  Four cases had Acute Motor and 
Sensory Axonal Neuropathy (AMSAN) variant and one 
had Acute Motor Axonal Neuropathy (AMAN) variant of 
GBS. However, in the Italian case series, the author 
reported their NCS/EMG as a mixed picture whereas in 
our opinion, a prolong DML and absent F waves favors 
a demyelinating variant. 26
Treatment
Three cases were ambulatory with minimum motor 
deficit and were not offered any treatment for GBS. One 
of them was a Miller Fisher variant. Nineteen patients 
were given IVIG. Among these two cases had repeat 
sessions of IVIG and two cases had PLEX after IVIG due 
to initial inadequate response. Two case had PLEX 
sessions as primary treatment one among them had 
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients 
were either discharged to nursing homes or shifted to 
rehabilitation for exercise. Complete recovery was 
reported in eight patients. At the time of publication of 
cases, three patients were on mechanical ventilation, 
one was critically ill, and no improvement was reported 
in one case.  Outcome and discharge status were not 
mentioned for three cases.
 
Discussion
This review suggests that COVID-19 associated GBS 
has emerged as an important neurological 
manifestation and complication of this global 
pandemic. Experts have suggested that in this 
pandemic any patient presenting with an acute 
paralytic disease-like GBS, may represent the first 
manifestation of COVID-19.40 It is therefore important 
to know the clinical features and associated 
manifestations in a case of GBS due to COVID-19. 
Although, a clear association of COVID-19 leading to 
triggering of GBS is lacking at present, experience with 
Zika Virus associated GBS suggests a possibility of 
causality between GBS and COVID-19 infection. The 
onset of GBS was post infectious in all the cases in this 
review, except three in which it was para infectious. A 
similar pattern has also been seen in Zika Virus 
infections. Therefore, the treating physician should 
have a high index of suspicion in managing such cases. 
The patient might be in the infective stage of COVID-19 
and personal protective equipment will be necessary for 
the safety of hospital staff. Lung changes due to 
COVID-19 infection were seen in many patients in this 
review (15/24). Fourteen had a positive HRCT and one 
had pneumonia on X ray chest. All these cases had a 
positive Nasopharyngeal PCR. Therefore, it is important 
to consider that during the current pandemic 
respiratory compromise in GBS may not be entirely due 
to neuromuscular failure but may also be due to 
COVID-19 pneumonia. At the same time if the patient 
with COVID-19 is having deterioration of respiratory 
function or is difficult to wean from ventilator GBS 
should also be considered as one of the possible 
reasons. This review suggests that in COVID-19 
associated GBS, AIDP variant is more common 
followed by AMAN and AMSAN variants. However, 
Umapathi has recently suggested that there is a 
possibility that there may be an underlying paranodal 
axonal pathology in these cases and serial EDX follow 
up studies might help in reaching a firm conclusion 
about the actual nature of the problem.41 Three 
patients presented as Miller Fisher syndrome variants 
of GBS. Similarly, craniobulbar involvement was seen in 
four cases beside three quoted above. This is a large 
number considering the very low incidence of Miller 
Fisher syndrome variant of GBS in general population. 
The experience with Zika virus related GBS suggests 
that the patient present with typical symptoms 
including facial palsy on presentation, male 
predominance, and AIDP on EDX. A similar pattern was 
documented in this review. In a review from Puerto Rico 
facial weakness was seen in 62% cases of Zika Virus 
associated GBS as compared with 10% in non- Zika 
related GBS.42 In this review 37.5 % of the cases had 
facial weakness with 5 having bilateral facial paralysis. 
The incidence of dysphagia in Zika Virus associated 
GBS has been reported to be 53.5% while it is low in 
COVID-19 associated GBS 5/24 (20%). Two patients 
had paraparesis at presentation followed by urinary 
retention and were later diagnosed as GBS. 29,39 This 
paraparetic pattern is seen more commonly in Zika 
Virus associated GBS cases. We do not know the exact 
mechanism of this phenomenon. In 5 cases hyposmia 
and hypogeusia were either the presenting or 
co-existing features. 28,34 These were likely due to the 
COVID-19 infection and not because of GBS. This is an 
important finding and can be used as a clinical 
indicator of COVID-19 infections in suspected GBS 
cases. Especially if this is combined with the presence 
of lymphopenia on blood counts and the presence of 
other cranial neuropathies on examination. 
Seropositivity of GBS for ganglioside antibody is 
reported to be around 30% with the cases of MFS 
having 95% GQ1b positivity. In this review only one 
case was positive GD 1b ganglioside antibody. However, 
this data is too small to make a conclusion. Most of the 
cases in this review were treated with 5 sessions of 
IVIG. In two cases, IVIG was repeated while in two 
cases PLEX was also done after giving IVIG. PLEX has 
been used in two cases as initially and in one it was 
followed by IVIG due to inadequate response. One of 
the possible reasons for use of frequent use of IVIG in 
all these cases is that all of them were in high income 
countries with adequate resources and easy access to 
IVIG. We would like to suggest that in resource 
constrained areas and the developing world PLEX might 
prove to be equally beneficial as this is the preferred 
mode of treatment in cytokine storm syndrome due to 
COVID-19.43  Most of the patients had a good outcome 
and were either discharged to home with complete 
recovery or were referred to rehabilitation for 
management of residual weakness and motor deficits. 
There was one death, and four patients were reported 
to be on mechanical ventilation at the time of 
publication of the case reports. However, due to the 
limited data, it is difficult to comment if COVID-19 
associated GBS increases severity of illness, length of 
Intensive care Unit (ICU) admission and prolongs 
ventilatory support along with residual disability at six 
months post treatment.
Comparison of MERS associated GBS Vs. 
COVID-19 associated GBS
The published data regarding neurological complication 
and manifestations associated with MERS is limited. 
44,27,28  In addition,  MERS was an epidemic limited to 
one geographic area and GBS associated with MERS 
was rarely reported so it is not possible to make a 
detailed comparison between this  and COVID-19 
associated GBS due to paucity of data. There is one 
case report of a critical illness neuropathy due to 
prolong intensive care unit stay reported from Saudi 
Arabia.45 Kim et.al identified only four cases from Korea 
during the 2015 our break of MERS, which presented 
with neurological features. 26 One was diagnosed as 
GBS Bickerstaff variant, second one as Intensive care 
unit associated neuropathy overlapping with GBS and 
last 2 were labeled as toxic neuropathy. All four had 
sensory features on presentation and one of them 
developed motor weakness and ophthalmoplegia. 
However, EDX evaluation and CSF examination was 
normal in all patients. Ganglioside antibody was also 
negative. Only one patient required mechanical 
ventilation and was given IVIG. The other three did not 
have motor weakness and were only kept under 
medical observation, provided supplemental oxygen 
and no specific treatment was offered. These 
epidemics limited to a specific geographic zone 
affecting only 2494 people (WHO estimates), unlike 
COVID-19 which is a global health care crisis affecting 
millions.  However, the common feature among both is 
the craniobulbar involvement in both.46
Comparison of Zika Virus associated GBS Vs. 
COVID-19 associated GBS
The comparison of GBS due to COVID-19 with Zika 
Virus associated is presented in Table 3.  In Zika 
Virus-GBS the median time from symptoms to disease 
onset was seven days consistent with para infectious 
GBS whereas in this review the median time was 11 
days (3-28) days. In Zika Virus GBS the disease was 
more aggressive with frequent ICU admission and need 
for ventilatory support. Our data reports a similar 
pattern with a total of nine patients needing respiratory 
support. Seven were placed on mechanical ventilation 
and two were on noninvasive ventilation. On EDX 
evaluation demyelinating type is the most finding both 
with Zika Virus and COVID-19 associated GBS. Cranial 
involvement is another feature common to both types 
of GBS.
Limitations
Despite a rigorous search methodology used for this 
scoping review, we were not able to perform literature 
search across every major English bio-medical 
literature search database due to lack of resources and 
access. There is a possibility that we might have missed 
some cases which hopefully will be identified in the 
systematic reviews registered in the International 
prospective register of systematic reviews.  The total 
number of confirmed cases of COVID-19 globally as of 
May 2020 were more than 7 million but we were able 
to document only 24 cases of GBS reported in the 
English biomedical literature. This is a small number of 
cases to make a causal relationship or a definitive 
conclusion regarding COVID-19 associated GBS. Due 
to the wide spread of the disease and wide variations in 
the documentation and reporting of data from different 
parts of the world, there are chances that mild cases of 
GBS or cases with limited involvement might be missed 
or do not report to hospitals. Moreover, neurological 
services are not widely available in many developing 
countries and there is a possibility that some COVID-19 
associated GBS cases remain undiagnosed due to lack 
of expertise in neurology.  In addition, mortality in 
COVID-19 cases due to rapidly progressive respiratory 
failure is usually attributed to the COVID-19 itself. There 
is a possibility of co-existing GBS which may contribute 
to the worsening of the condition. We hope that as 
more data from different parts of the world is shared, 
things will become clearer in future and provide further 
insights into the COVID-19 associated GBS. 
Conclusion
The primary presentation of COVID-19 is respiratory but 
neurological manifestations and complications are 
increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with 
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed 
to establish the casualty.  However, from the available data we conclude that most of the cases present as a 
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of 
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is 
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale 
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate 
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy;  CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange;  UL; upper 
Limb
Table 2:  Details of the diagnostics, management, and outcomes of COVID-19 related GBS
ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN: 
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous 
Immunoglobulins; HRCT; High Resolution Computed Tomography scan;  LL: lower limbs; ;MRC: Medical Research 
Council;  MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper 
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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